AstraZeneca Return on Tangible Equity 2010-2024 | AZN
Current and historical return on tangible equity values for AstraZeneca (AZN) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| AstraZeneca Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2024-03-31 |
$6.33B |
$-21.31B |
-31.05% |
| 2023-12-31 |
$5.96B |
$-18.97B |
-28.45% |
| 2023-09-30 |
$5.90B |
$-20.41B |
-27.17% |
| 2023-06-30 |
$6.16B |
$-20.87B |
-27.23% |
| 2023-03-31 |
$4.71B |
$-23.48B |
-20.14% |
| 2022-12-31 |
$3.29B |
$-22.07B |
-13.87% |
| 2022-09-30 |
$2.04B |
$-24.14B |
-8.51% |
| 2022-06-30 |
$-1.25B |
$-23.77B |
5.22% |
| 2022-03-31 |
$-1.06B |
$-24.87B |
4.81% |
| 2021-12-31 |
$0.11B |
$-23.10B |
-0.55% |
| 2021-09-30 |
$1.47B |
$-24.27B |
-7.82% |
| 2021-06-30 |
$3.77B |
$-16.11B |
-21.66% |
| 2021-03-31 |
$3.98B |
$-17.67B |
-22.33% |
| 2020-12-31 |
$3.20B |
$-17.15B |
-17.60% |
| 2020-09-30 |
$2.50B |
$-18.71B |
-13.61% |
| 2020-06-30 |
$2.15B |
$-17.72B |
-11.60% |
| 2020-03-31 |
$1.52B |
$-19.07B |
-8.09% |
| 2019-12-31 |
$1.34B |
$-17.91B |
-6.79% |
| 2019-09-30 |
$2.06B |
$-19.38B |
-10.23% |
| 2019-06-30 |
$2.19B |
$-18.85B |
-10.47% |
| 2019-03-31 |
$2.41B |
$-22.50B |
-11.06% |
| 2018-12-31 |
$2.16B |
$-19.62B |
-9.83% |
| 2018-09-30 |
$2.42B |
$-22.61B |
-10.83% |
| 2018-06-30 |
$2.68B |
$-22.33B |
-11.85% |
| 2018-03-31 |
$2.80B |
$-23.11B |
-12.21% |
| 2017-12-31 |
$3.00B |
$-21.37B |
-12.91% |
| 2017-09-30 |
$3.54B |
$-23.52B |
-15.04% |
| 2017-06-30 |
$3.87B |
$-23.83B |
-16.11% |
| 2017-03-31 |
$3.39B |
$-24.30B |
-13.81% |
| 2016-12-31 |
$3.50B |
$-22.58B |
-14.16% |
| 2016-09-30 |
$2.47B |
$-25.40B |
-10.69% |
| 2016-06-30 |
$2.22B |
$-25.90B |
-10.99% |
| 2016-03-31 |
$2.92B |
$-24.97B |
-17.03% |
| 2015-12-31 |
$2.83B |
$-15.94B |
-19.35% |
| 2015-09-30 |
$1.70B |
$-14.06B |
-12.26% |
| 2015-06-30 |
$1.18B |
$-13.65B |
-8.98% |
| 2015-03-31 |
$1.28B |
$-14.75B |
-10.33% |
| 2014-12-31 |
$1.23B |
$-12.89B |
-10.62% |
| 2014-09-30 |
$1.03B |
$-11.25B |
-11.34% |
| 2014-06-30 |
$2.02B |
$-10.66B |
-28.04% |
| 2014-03-31 |
$2.05B |
$-11.66B |
-38.81% |
| 2013-12-31 |
$2.56B |
$-2.78B |
-79.21% |
| 2013-09-30 |
$4.59B |
$-3.75B |
-146.40% |
| 2013-06-30 |
$4.85B |
$-2.94B |
-148.14% |
| 2013-03-31 |
$5.63B |
$-3.44B |
-196.95% |
| 2012-12-31 |
$6.24B |
$-2.40B |
-348.36% |
| 2012-09-30 |
$6.23B |
$-4.32B |
-1163.19% |
| 2012-06-30 |
$8.19B |
$-1.26B |
682.95% |
| 2012-03-31 |
$8.71B |
$0.82B |
439.47% |
| 2011-12-31 |
$9.99B |
$2.62B |
530.40% |
| 2011-09-30 |
$10.13B |
$2.62B |
644.03% |
| 2011-06-30 |
$8.21B |
$1.87B |
1038.41% |
| 2011-03-31 |
$8.21B |
$0.43B |
3722.90% |
| 2010-12-31 |
$8.08B |
$1.38B |
-2070.21% |
| 2010-09-30 |
$8.01B |
$-0.51B |
-756.28% |
| 2010-06-30 |
$8.57B |
$-0.41B |
-544.56% |
| 2010-03-31 |
$8.16B |
$-2.02B |
-328.91% |
| 2009-12-31 |
$7.53B |
$-1.29B |
-210.97% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$238.424B |
$45.811B |
|
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
|
